Compare Aventis Pharma with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ALEMBIC LTD - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ALEMBIC LTD SANOFI INDIA/
ALEMBIC LTD
 
P/E (TTM) x 35.1 73.7 47.5% View Chart
P/BV x 6.1 2.6 234.5% View Chart
Dividend Yield % 1.4 0.4 364.4%  

Financials

 SANOFI INDIA   ALEMBIC LTD
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
ALEMBIC LTD
Mar-18
SANOFI INDIA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs6,84072 9,500.1%   
Low Rs4,63034 13,657.8%   
Sales per share (Unadj.) Rs1,203.14.7 25,595.2%  
Earnings per share (Unadj.) Rs165.36.1 2,707.6%  
Cash flow per share (Unadj.) Rs209.96.2 3,360.3%  
Dividends per share (Unadj.) Rs84.000.20 42,000.0%  
Dividend yield (eoy) %1.50.4 387.8%  
Book value per share (Unadj.) Rs963.640.7 2,369.9%  
Shares outstanding (eoy) m23.03267.03 8.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.811.3 42.3%   
Avg P/E ratio x34.78.7 400.0%  
P/CF ratio (eoy) x27.38.5 322.3%  
Price / Book Value ratio x6.01.3 457.0%  
Dividend payout %50.83.3 1,551.2%   
Avg Mkt Cap Rs m132,07814,139 934.1%   
No. of employees `0003.3NA-   
Total wages/salary Rs m4,068207 1,961.4%   
Avg. sales/employee Rs Th8,393.8NM-  
Avg. wages/employee Rs Th1,232.4NM-  
Avg. net profit/employee Rs Th1,153.0NM-  
INCOME DATA
Net Sales Rs m27,7081,255 2,207.5%  
Other income Rs m897370 242.3%   
Total revenues Rs m28,6051,625 1,759.9%   
Gross profit Rs m6,235111 5,612.1%  
Depreciation Rs m1,02738 2,716.9%   
Interest Rs m72 411.8%   
Profit before tax Rs m6,098442 1,380.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,29224 9,569.9%   
Profit after tax Rs m3,8061,630 233.5%  
Gross profit margin %22.58.9 254.2%  
Effective tax rate %37.65.4 693.3%   
Net profit margin %13.7129.8 10.6%  
BALANCE SHEET DATA
Current assets Rs m15,9221,867 852.8%   
Current liabilities Rs m6,235591 1,054.6%   
Net working cap to sales %35.0101.6 34.4%  
Current ratio x2.63.2 80.9%  
Inventory Days Days6494 67.5%  
Debtors Days Days2174 28.4%  
Net fixed assets Rs m7,5391,791 421.0%   
Share capital Rs m230534 43.1%   
"Free" reserves Rs m21,96210,324 212.7%   
Net worth Rs m22,19210,858 204.4%   
Long term debt Rs m041 0.0%   
Total assets Rs m29,83911,591 257.4%  
Interest coverage x872.1260.9 334.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.1 857.5%   
Return on assets %12.814.1 90.8%  
Return on equity %17.215.0 114.3%  
Return on capital %27.515.2 181.1%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m7,58719 39,108.2%   
Fx outflow Rs m7,145264 2,708.3%   
Net fx Rs m442-244 -180.8%   
CASH FLOW
From Operations Rs m3,739236 1,585.7%  
From Investments Rs m-731-224 326.3%  
From Financial Activity Rs m-1,972-27 7,413.5%  
Net Cashflow Rs m1,036-15 -7,000.0%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.2 7,200.0%  
FIIs % 14.6 9.7 150.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 26.1 40.2%  
Shareholders   15,184 54,701 27.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   PROCTER & GAMBLE HEALTH  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 20, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS